Gentamicin Adverse Effects
Gentamicin causes three major adverse effects: nephrotoxicity (most common), ototoxicity (most serious), and neurotoxicity, with risk increasing substantially with cumulative dose, prolonged therapy, advanced age, and pre-existing renal impairment.
Primary Adverse Effects
Nephrotoxicity
Nephrotoxicity is the most frequently encountered adverse effect of gentamicin 1:
- Incidence: Occurs in approximately 2-8.7% of patients, with higher rates in those with risk factors 2, 1
- Manifestations: Rising BUN, serum creatinine, oliguria, presence of casts/cells/protein in urine
- Reversibility: The large majority of cases are reversible, particularly with single-dose regimens 3
- Risk factors:
- Pre-existing renal impairment (especially dialysis patients)
- Longer treatment duration or higher cumulative doses
- Concurrent nephrotoxic agents
- Advanced age (>60 years)
- Female sex
- Higher body weight
- ICU admission
- Concurrent CT contrast imaging 4
Critical caveat: Gentamicin should be avoided entirely in patients >60 years of age due to sharply increased risk of kidney injury 4.
Ototoxicity
Ototoxicity represents the most serious adverse effect due to potential irreversibility 2, 5, 1:
- Types: Both vestibular dysfunction (dizziness, vertigo) and auditory damage (tinnitus, hearing loss)
- Incidence: Ranges from 1.5-24% depending on dose and duration, with hearing loss at 3% in neonates 2, 5, 6
- Characteristics:
- Hearing loss typically begins with high-frequency diminution
- May be irreversible
- Risk increases dramatically with cumulative doses >100-120 g
- Risk factors:
- Advanced age
- Concurrent loop diuretics (furosemide, ethacrynic acid)
- Prolonged therapy
- Higher single doses
- Pre-existing renal impairment
Neurotoxicity
Less common but clinically significant 2, 5, 1:
- Common: Circumoral paresthesias immediately post-injection
- Rare but serious:
- Peripheral neuropathy
- Encephalopathy (numbness, muscle twitching, convulsions)
- Myasthenia gravis-like syndrome
- Respiratory depression
- Interaction with muscle relaxants causing postoperative respiratory weakness
Secondary Adverse Effects
Additional reported reactions include 1:
- Hypersensitivity: Rash, urticaria, anaphylactoid reactions, fever
- Gastrointestinal: Nausea, vomiting, stomatitis
- Hematologic: Anemia, leukopenia, thrombocytopenia, eosinophilia
- Electrolyte disturbances: Hypomagnesemia, hypocalcemia, hypokalemia (may cause tetany and muscle weakness)
- Hepatic: Increased transaminases, LDH, bilirubin
- Local: Pain at injection site (rare), subcutaneous atrophy
Special Populations
Pregnancy
Gentamicin is absolutely contraindicated in pregnancy due to risk of fetal nephrotoxicity and congenital hearing loss 2, 5, 2.
Renal Impairment
Dosing adjustments are essential 2, 5:
- Reduce dosing frequency to 2-3 times weekly when creatinine clearance <50 mL/min
- Maintain mg/kg dose at 12-15 mg/kg to preserve concentration-dependent bactericidal effect
- Administer after dialysis
- Monitor serum drug concentrations mandatory
Elderly Patients
- Reduce maximum daily dose to 10 mg/kg (750 mg) for patients >59 years 2, 5
- Consider avoiding gentamicin entirely in patients >60 years 4
Risk Mitigation Strategies
Monitoring Requirements
- Audiogram and vestibular testing
- Romberg testing
- Serum creatinine
Monthly monitoring:
- Renal function assessment
- Questioning regarding auditory/vestibular symptoms
- Repeat audiogram if symptoms develop
Dosing Considerations
For enterococcal endocarditis specifically 7:
- Multiple divided doses (total ≈3 mg/kg/day) preferred over single daily dosing
- Target 1-hour serum concentration ≈3 μg/mL, trough <1 μg/mL
- Consider limiting gentamicin duration to 2 weeks to minimize toxicity while maintaining efficacy 8
- Gentamicin-associated nephrotoxicity may complicate 4-6 week courses and could result in life-threatening complications including hemodialysis requirement 7
Circadian Considerations
Emerging evidence suggests toxicity varies with circadian timing of administration, with treatment at the beginning of the rest span (14 hours after lights on) showing reduced ototoxicity and nephrotoxicity compared to treatment at the beginning of the activity span 9.